Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laryngeal amyloidosis.

Journal of insurance medicine (New York, N.Y.)·2012
Same author

The blue rubber bleb [corrected] nevus syndrome.

Journal of insurance medicine (New York, N.Y.)·2009
Same author

Testicular microlithiasis.

Journal of insurance medicine (New York, N.Y.)·2006
Same author

Sleep apnea.

Journal of insurance medicine (New York, N.Y.)·2006
Same author

Cardiac valvular tumors: cardiac papillary fibroelastoma.

Journal of insurance medicine (New York, N.Y.)·2004
Same journal

Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

The Smoking Dilemma: A Technical Deep Dive.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Biological Clocks: Ready for Prime Time?

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Identifying Benzodiazepine Abuse: A Report of 3 Cases.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Between Fear and Adoption: The AI Paradox in Medico-Legal Practice Among National Insurance Physicians.

Journal of insurance medicine (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Neuromyelitis optica.

Robert M Feingold1

  • 1William Penn Life Insurance Company of New York, 100 Quentin Roosevelt Blvd, Garden City, NY 11530, USA. rfeingold@gamerica.com

Journal of Insurance Medicine (New York, N.Y.)
|January 6, 2009
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica (NMO) is a rare central nervous system disorder causing optic neuritis and transverse myelitis. Differentiating NMO from multiple sclerosis is crucial, as NMO-IgG presence aids diagnosis, though prognosis remains poor despite immunosuppressants.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Related Experiment Videos

Last Updated: Jun 26, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Area of Science:

  • Neuroimmunology
  • Central Nervous System Disorders

Background:

  • Neuromyelitis optica (NMO) is an autoimmune demyelinating disease affecting the central nervous system.
  • NMO commonly presents with optic neuritis and transverse myelitis, often leading to misdiagnosis as multiple sclerosis (MS).

Purpose of the Study:

  • To highlight key differentiating features between NMO and MS.
  • To emphasize the diagnostic significance of NMO-IgG.
  • To discuss current treatment and prognosis of NMO.

Main Methods:

  • Review of clinical presentations and diagnostic markers for NMO.
  • Comparison of NMO and MS characteristics.
  • Analysis of treatment outcomes and prognostic factors in NMO.

Main Results:

  • NMO is characterized by distinct clinical and serological profiles compared to MS.
  • NMO-IgG is a critical biomarker for differentiating NMO from MS.
  • Despite immunosuppressive therapy, NMO often carries a poor prognosis.

Conclusions:

  • Accurate differentiation of NMO from MS is essential for appropriate management.
  • NMO-IgG testing significantly improves diagnostic accuracy.
  • Further research is needed to improve the long-term prognosis for NMO patients.